# Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $529,313

## Abstract

The use of nano-enabled chemotherapy to trigger an immune response to pancreatic ductal adenocarcinoma
(PDAC) introduces a novel approach for overcoming robust barriers to immunotherapy, including poor
immunogenicity, low neoantigen burden, stromal interference (“T-cell exclusion”), overexpression of
indoleamine 2,3-dioxygenase (IDO-1), and the immune privileged environment of the liver favoring metastatic
spread. Our preliminary data show that lipid-bilayer coated mesoporous silica nanoparticles (silicasomes)
provide an effective platform for inducing immunogenic cell death (ICD) by delivering prescreened
chemotherapeutic agents to the PDAC site. ICD promotes the presentation of endogenous tumor antigens
cells, raising the hypothesis that ICD offers a promising endogenous vaccination approach to generate a “hot”
tumor microenvironment (TME) that can be propagated by co-delivery of drugs interfering in regionally
overexpressed immunosuppressive pathways. These pathways can be targeted by inhibitors of IDO-1, CXCR4
(T-cell exclusion) and glycogen synthase kinase 3 (which controls PD-1 expression). We also propose that
metastatic spread can be reduced by ICD-induced memory T-cells and delivery of “stimulator of interferon
genes” (STING) agonists to tolerogenic antigen presenting cells in the liver. The long-term goal of our
interdisciplinary efforts is to develop a chemo-immunotherapy platform for delivery of ICD stimuli by the
silicasome contemporaneous with inhibitors of immune checkpoint and T-cell exclusion pathways (CXCR4).
The objectives include the use of innovative drug loading and cholesterol-conjugated prodrugs to synthesize
silicasomes that can be used to obtain the best synergy between ICD stimuli and inhibitors of
immunosuppressive pathways in orthotopic and genetic engineered PDAC models. This requires research
discovery into the mechanistic basis of synergy between ICD and regional immune escape pathways. We will
use an integrin-targeting, tumor-penetrating iRGD peptide to enhance drug delivery by a transcytosis pathway.
We will also construct polymeric nanocarriers to deliver STING agonists for preventing metastatic spread to the
liver. The rationale is that the use of an ICD approach to generate a “hot” tumor environment will facilitate
combination immunotherapy with improvement of PDAC mortality. We plan to test our hypothesis by pursuing
the following specific aims: Aim 1: To develop a nano-enabled chemo-immunotherapy platform for PDAC that
utilizes an endogenous (ICD-mediated) treatment approach plus interference in regionally overexpressed
immune checkpoint pathways to generate a “hot” tumor environment. Aim 2: To enhance the immunotherapy
impact of the ICD platform by using integrin-targeting, tumor-penetrating iRGD peptides and developing a
silicasome that interferes in T-cell exclusion in the stroma through the delivery of CXCR4 inhibitors. Aim #3: To
reprogram the immune suppressive effects of liver APC by STING nanoparticl...

## Key facts

- **NIH application ID:** 10417161
- **Project number:** 5R01CA247666-03
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Andre Elias Nel
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $529,313
- **Award type:** 5
- **Project period:** 2020-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10417161

## Citation

> US National Institutes of Health, RePORTER application 10417161, Use of a Nano-Enabled Platform for Pancreatic Cancer Immunotherapy (5R01CA247666-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10417161. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*